Author: admin

Eisai and BIAL will present new research on Zebinix ® data at the International Congress of epilepsy

|

Eisai and BIAL be presented new research data about international epilepsy Congress ® Zebinix

HATFIELD, United Kingdom, August 29, 2011/PRNewswire /-

have been accepted 25 abstracts for presentation

Eisai and BIAL announced today that 25 abstracts that highlight the extensive program of development of Zebinix ® (eslicarbacepina acetate), have been accepted for presentation during the 29 International Congress of epilepsy to be held in Rome from August 28 to September 1, 2011. Presentations evaluating the use of acetate eslicarbacepina as monotherapy, its efficacy and safety in children with crisis of partial onset, cognitive effects as complementary therapy in children and their possible use in elderly patients with partial onset seizures *. Zebinix ® (eslicarbacepina acetate) is approved in Europe as adjuvant therapy for use in adults with partial onset seizures, with or without secondary generalization.[1] The continuous development programme is aimed to expand treatment options for patients with epilepsy.

“ We know from previous clinical trials and clinical practice continuous eslicarbacepina acetate is an effective complementary therapy for adults with partial onset seizures, with or without secondary generalization, whose dose is easy to adjust, well tolerated and allows to manage a single daily dose. The results of these clinical trials, together with the extensive program of clinical trials, highlights the potential of Zebinix ® to improve seizure control and expand its use in epilepsy. ” Professor Eugen Trinka, Universitätsklinik für Neurologie, Universität Salzburg, Austria.

A clinical trial involving 170 centres in 30 countries to investigate the efficacy and safety of acetate again diagnostic eslicarbacepina as monotherapy first-line 900 adults, compared with the controlled-release carbamazepine globally is being conducted. This study fully complies with current European guidelines and can be an essential step to broaden the options of treatment of patients with epilepsy.

“ The results of this study and other planned studies reinforce of Eisai and BIAL commitment to the development and commercialization of new treatments that help improve the lives of people with epilepsy. We are proud of our commitment in this area and look forward to seeing the results of studies in monotherapy, children and elderly ”, says the DRA. Bettina Bauer, Director of the epilepsy for the EU, Eisai Europe business unit.

After the identification of the target dose of acetate of eslicarbacepina in children, being an essay which proposes to offer the first data on the efficacy and safety of acetate eslicarbacepina in the treatment of Pediatric partial onset seizures. As cognitive comorbidity has special significance in children with epilepsy, because of its effects on learning and psycho-social interaction, is being conducted a second Pediatric study in children and adolescents with treatment resistant partial onset seizures for assessing cognitive effects and safety of adjuvant eslicarbacepina acetate. The effects of cognitive using the UBC, a battery of cognitive tests validated, will evaluate and will link with evolutionary changes and progression of the disease occur in the population of the study.

Epilepsy rates are higher in the elderly than in any other patient population; However, rarely includes patients with more than 65 years in large clinical trials due to the increased risk of side effects and the possibility of Pharmacokinetic disturbances. It has previously demonstrated that the pharmacokinetics of eslicarbacepina acetate is similar in young healthy volunteers and in the elderly, suggesting that eslicarbacepina acetate can be a useful treatment in this patient population option. The current study aims to assess the effects of acetate eslicarbacepina on the frequency of crises and their safety when used as adjunctive therapy in elderly patients.

Studies in specific patient populations, also the use of eslicarbacepina acetate in a wider adult population has been evaluated and the results will be presented at the Rome 2011 CIS. The results of an analysis a posteriori of the efficacy and safety in patients with partial onset seizures showed patients continuing treatment with carbamazepine resistant to respond well to adjuvant eslicarbacepina acetate.[2]

Is anticipated that the trials are concluded between 2012 and 2013 and the results will help guide future treatment options for adults with epilepsy patients, as well as for the specific populations of pediatric patients and elderly.

Read More

The largest international record of stable coronary artery disease shows that there is a lot of patients who maintain too high resting heart rate reference values

|

the largest registration of stable coronary artery disease shows that there is a lot of patients who maintain too high values of reference at rest heart rate

Paris, August 29, 2011/PRNewswire / – CLARIFY results, the largest international record never done before in outpatients with stable coronary artery disease (CAD)shows that despite the extensive use of beta blockers, one-third of the patients with CAD had a heart rate at rest (FCR) of 70 lpm.[1] This value of heart rate, previously has been linked with a higher prevalence and greater severity of angina and myocardial infarction.[2] Results of CLARIFY, representing more than 30,000 patients in 45 countries around the world, presented today at the Congress of the society European’s cardiology.

The CAD continues to be the leading cause of death worldwide.[3] A better understanding of the treatment and cardiovascular outcomes for these patients is key to reducing the burden of the disease.

The registry must (ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) was designed to increase our knowledge and understanding of the CAD, even with an assessment of the role of the heart rate (FC) in the prognosis of patients with CAD. It aims to improve the treatment of disease by identifying the gaps between the existing evidence and actual practice.

CLARIFY included 33.649 patients around the world between November 2009 and July 2010. The average age of patients was 64±11 years, 77.5% of whom were men. FC average pulse was 68, 3±10, 6 lpm, while the FC for ECG was 67, 2±11, 5 lpm. 44% Of patients had a FC at rest > = 70 lpm. In addition, in analyses adjusted, the FC > 70 lpm was independently associated with a higher prevalence and severity of angina, and more frequent episodes of ischemia. “

“”For some years we know that heart rate (FC) is a risk factor potentially important in the DAC, but so far we had relatively little information on heart rate among patients with CAD outside the hospital,” says the President must, Professor Gabriel Steg to the Hopital Bichat ParisFrance. “For the first time, we can see that many patients with CAD have elevated resting heart rate, and a combination of evidence showing now must, as anecdotal evidence from previous sources indicate that it is associated with symptoms and worse outcomes.” “These results suggest that a tighter control over the reference value of heart rate with drugs to lower the heart rate can benefit patients with CAD to improve control of symptoms and their prognosis”.

More than 90% of patients registered in CLARIFY were treated with aspirin and Statins, and 75% with beta-blockers, indicating a large intake of evidence-based medicine for secondary prevention. “It is encouraging to see that the majority of patients with CAD receive treatments in line with guidelines,” says Professor Steg. “The results presented today are just the beginning.” “It must have a potential five-year follow-up, and each year will provide relevant information.”

The register must is funded by an educational grant from Servier laboratories. Data are collected and analyzed in the Robertson Centre for Biostatistics in Glasgow, United Kingdom, under the direction of Professor Ian Ford, and the study is led by an academic Executive Committee chaired by Professor p. g. Steg.

p

Read More

Jennewein Biotechnologie and Pfizer Nutrition collaborate in human milk components

|

Jennewein Biotechnologie and Pfizer Nutrition collaborate in human milk components

RHEINBREITBACH, Germany, August 29, 2011/PRNewswire /-

• license agreement gives rights to Pfizer Nutrition for innovative human milk components and biological sources

Jennewein Biotechnologie today announced that the company has signed a license agreement with Pfizer Nutrition to develop and commercialize two human oligosaccharides of milk (HMOs).

The human milk oligosaccharides represent a prominent component of the milk of the mother, in addition to providing short and long term benefits for children from birth onwards. Scientific research has shown that the HMOs can reduce significantly the risk of infection of children during their time of lactation. In addition, these compounds are known to influence the colonization of beneficial bacteria and support healthy immune development.

The Association will focus on allowing the functional and immunological benefits from the HMOs to be available in the face of the children that are fed with formulas for children. Human milk, the “ gold standard ” thanks to its special composition of lipids, proteins and HMOs, is the best nutrition for children.

“ An experience close to a century as pioneers in nutritional science for children, we are improving steadily to more closely replicate the composition and functional benefits of breast milk, and this partnership really helps to achieve this objective ”, stated John Troup, PhD and Vice President of research and overall development of Pfizer Nutrition.

Dr. Stefan Jennewein, managing director and co-founder of Jennewein Biotechnologie, stressed: “ complex oligosaccharides in general and the HMOs in particular have shown great potential for use in human nutrition. Cooperation between Pfizer Nutrition and Jennewein Biotechnologie will accelerate the development in this field to meet the specific additional skills ”.

Jennewein plans to also focus on nutrition for adults, apart from in the formulas for children, and in the marketing of the HMOs to bring the benefits of this natural product to a broader group of consumers.

About Jennewein Biotechnologie

Jennewein Biotechnologie GmbH, founded in 2005 in Rheinbreitbach (Germany), is a scientific company based in the field of industrial biotechnology. The company focuses its activities on the development of innovative production processes for rare and complex Monosaccharides and oligosaccharides. Jennewein NRC aims to provide sugar with scientifically proven health benefits and make them available for large groups of consumption.

About Pfizer Nutrition

Pfizer Nutrition, formerly Wyeth Nutrition, is part of Pfizer Inc. Pfizer Nutrition supports the goal of the company to improve the health and well-being in each of the stages of life, providing depth and breadth to consumers and scientific vision to new people and new markets around the world. Pfizer Nutrition brings together nearly a century of experience in which the company has provided clinical rigor, scientific research, global manufacturing and product safety standards to boost scientific outstanding solutions that offer confidence to parents, help children grow and support your healthy future. We develop nutritious products with premium quality which have been designed in a scientific way to meet the needs of young people and children, as well as pregnant mothers and lactation phase.

Read More

In its list of the year 2011 Inc.500 has selected Jose Prendes, President and Director of PureFormulas.com, as one of “10 best entrepreneurs Hispanics”

|

in its list of the year 2011 Inc.500 has selected Jose Prendes, President and Director of PureFormulas.com, as one of “Top 10 entrepreneurs-Hispanic”

MIAMI, August 29, 2011 PRNewswire-HISPANIC PR WIRE /- José l. Prendes, President and Director of PureFormulas.com has been selected by Inc.500 as one of “Top 10 entrepreneurs-Hispanic”. PureFormulas.com, a company E-retailer that sells natural supplements with the highest standards of quality and purity, was also selected in the following lists of Inc.500 for year 2011: fastest-growing health services company; Company’s fastest-growing in Florida; and one of the best companies in the Miami metropolitan area.

José l. Prendes, a visionary entrepreneur born in Cuba, founded PureFormulas.com in 2007, and since then has become one of the fastest growing in the United States E-retailer. “We are thrilled to be recognized in the lists of Inc.500 as one of the companies of health services of fastest-growing, one of Florida’s fastest growing companies, and one of the best companies in the Miami metropolitan area.” “This confirms the tireless work of our team, their dedication and commitment to service excellent customer”.

Inc.500 is an exclusive list of the fastest growing nationwide companies. The list represents a comprehensive look at the most important segment of the economy: the United States independent entrepreneurs.

PureFormulas.com is also included in the following Inc.500 list for the year 2011:

-Inc. 500 List – PureFormulas.com Ranked # 97
http://www.inc.com/inc5000/list/2011

-Fastest Growing Health Companies – PureFormulas.com Ranked # 5
http://www.inc.com/inc5000/list/2011/industry/health

-Fastest growing companies in Florida – PureFormulas.com Ranked # 11
http://www.inc.com/inc5000/list/2011/state/fl

-Top companies in the Miami Metro Area – PureFormulas.com Ranked # 5
http://www.inc.com/inc5000/list/2011/metro/miami

-Top 10 Latino and Hispanic Entrepreneurs
http://www.inc.com/ss/2011-inc-5000-top-10-latino-and-hispanic-entrepreneurs

PureFormulas.com

founded in the year 2007, with headquarters in the city of Miami, Florida, PureFormulas.com (www.pureformulas.com) distributes the highest quality and purity natural supplements to over 150,000 clients across the nation and offers shipping free on over 15,000 products through its Web site. More than 30 participants trained in service to the client work daily in PureFormulas.com to serve the needs of its users, and a Board of experts in the health care, naturopaths and chiropractors, constantly collaborates with the company to keep up-to-date with the needs of its customers and the latest discoveries and advances in the field of health. The Mission of PureFormulas.com is to maintain motivation, enthusiasm and passion daily for a healthy lifestyle, at the time that maintains an excellent level of customer service and best quality products.

Read More

Syngene expands its current relations with CAS to offer all its scientists SciFinder ®

|

Syngene expands its current relations with CAS to offer all its scientists SciFinder ®

BANGALORE, India, August 29, 2011/PRNewswire /-

• SciFinder offers Syngene scientists access to an extensive chemical coverage, global patent information

Chemical Abstracts Service (CAS http://www.cas.org), the global leader in chemical information, announced today that Syngene International http://www.syngeneintl.com/syngene.asp, a subsidiary and international reputation of Biocon Limited contract research organization, the largest India biotechnology company, has signed a three year contract to provide its scientists unlimited access to SciFinder http://www.cas.org/products/scifindr/index.html, a CAS award winning chemistry research tool.

SciFinder offers Syngene the scope and depth of the chemistry required by scientists in global enterprises today. With daily updates of the contents of the database, SciFinder provides scientists with Syngene more timely information to help them progress in their investigation.

Using SciFinder, Syngene scientists have access to CAS REGISTRY (SM), the largest collection worldwide dissemination of information on chemicals, with a total of more than 61 million unique small molecular substances.

SciFinder also offers Syngene scientists access to global information on patents, allowing fast and reliable searches to help them identify options of research and make more new discoveries.

“ SciFinder is a critical tool that ensures that our scientists have the wide range of information needed to accelerate research, allowing the growth of our consumers and ensure that we remain competitive, global chemical ” said Dr. Manoj Nerurkar, head of discovery and development of small molecules in Syngene. “ CAS is an invaluable partner for our continued success in a market global dynamic ”

Syngene scientists will also benefit from SciPlanner ™, a new SciFinder feature which allows scientists more quickly identify synthesis options for designing better ways and approaches to research.

“ With an average of 1.8 million records of new substances originating of new global patent applications each year, is more important than ever before for researchers to access databases that reflect a commitment to the new chemistry that emerges from all sources, not only of a group of newspapers or limited patent coverage, ” said Christine McCue, Vice President of Marketing at CAS. “ The scope, depth and reliability of the chemical information provided by the CAS databases through SciFinder are incomparable. We are proud to extend access to SciFinder for Syngene scientists for synthesis and its full range of research needs chemistry. ”

On SciFinder

SciFinder ® is the leading chemists and researchers research tool, offering the substance and the proven results that scientists need to increase productivity and make discoveries fastestRapids. Intuitive, winning enforcement of an award provides instant access to CAS REGISTRY (SM) – the standard of gold’s compilations of chemical substances. Companies in Fortune 500, more than 1,800 universities and major government agencies worldwide rely on SciFinder to encourage r & d initiatives and promote innovation.

About CAS

Chemical Abstracts Service (CAS), a division of the American Chemical Society, is the world authority on chemical information. Our databases are curated and quality controlled by CAS scientists and are recognized by chemical and pharmaceutical companies, universities, governmental organizations and offices of patents worldwide as an authority. By combining these databases with research and analysis technologies advanced (products and services SciFinder ®, STN ® and Science IP ®), CAS offers the secure digital information environment more updated, complete and absorbing to scientific discoveries. Get more information at http://www.cas.org.

About Syngene

Founded in 1994, Syngene was the first India (CRO) contract research organization. In the last 16 years, have been associated with success with the leaders of the global pharmaceutical, biotechnology, chemical and agrochemical sectors in a wide range of discovery and development programs. Syngene offers multidisciplinary skills in chemistry, biology, development and extension of processes, formulation and analytical development and pre clinical services. His considerable group of scientific talents and modern r & d and production facilities enable the Organization to improve productivity and accelerate the delivery of all projects with the highest degree of professionalism. Get more information at http://www.syngeneintl.com/syngene.asp.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips